Okyo Pharma LTD

John P Brancaccio, a Director of OKYO Pharma Ltd, purchased 5,000 shares of common stock on July 21, 2026 for $1.48 per share.

Robert John Dempsey, CHIEF EXECUTIVE OFFICER and a Director of OKYO Pharma Ltd, purchased 15,000 shares of common stock on July 22, 2026 for $1.54 per share.

Gary S Jacob, CHIEF DEVELOPMENT OFFICER and a Director of OKYO Pharma Ltd, purchased 3,500 shares of common stock on July 21, 2026 for $1.40 per share.

Gabriele M Cerrone, a Director and 10% owner of OKYO Pharma Ltd, purchased 22,500 shares of common stock on July 21, 2026 for $1.45 per share.

Gabriele M Cerrone, a Director and 10% owner of OKYO Pharma Ltd, purchased 25,000 shares of common stock on July 20, 2026 for $1.40 per share.

Rajkumar Patil V., Chief Scientific Officer of OKYO Pharma Ltd, received 3,363 shares of common stock on July 27, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in OKYO Pharma Ltd, signaling a full exit from their position.

Woodline Partners LP has disclosed beneficial ownership of 7.0% of OKYO Pharma LTD's ordinary shares, holding 3,652,190 shares.

Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 7.7% of OKYO Pharma Ltd's ordinary shares as of March 31, 2026.

Jorey Chernett has filed an amended Schedule 13G, disclosing a 9.45% beneficial ownership stake in OKYO Pharma Ltd.

Dauntless Investment Group, LLC reports a 1.17% passive ownership stake in OKYO Pharma Ltd. as of December 31, 2025.

Jorey Chernett has filed an amendment to Schedule 13G, reporting beneficial ownership of 7.76% of OKYO Pharma Ltd's common stock as of September 30, 2025.